CSC’s Dynport Vaccine Company is Awarded UK Ministry of Defence Contract for Plague Vaccine Work
News Release -- September 29, 2010
FALLS CHURCH, Va., Sept. 29 – CSC (NYSE: CSC) announced today that the United Kingdom Ministry of Defence (UKMOD) awarded DynPort Vaccine Company LLC (DVC), a CSC company, a contract to scope the requirements for achieving licensure of the plague vaccine in the European Union. The contract was awarded during CSC’s fiscal 2011 first quarter.
Under the terms of the agreement, DVC will work with the London office of ERA Consulting (UK) Ltd. (ERA) to provide expertise on the licensure of the plague vaccine in the European Union. The vaccine candidate is designed to provide protection against the plague bacterium Yersinia pestis in aerosolized form and is currently in Phase 2 clinical trials. ERA has previously been authorized to have access to, and work on, US-based biodefense projects, for purposes of marketing authorization in Europe, consistent with the USA Patriot Act*. DVC is performing the work at its headquarters in Frederick, Md.
“We’ve made great strides in advancing the plague vaccine toward licensure under the U.S. Food and Drug Administration Animal Rule in the U.S.,” said Dr. Robert V. House, president of DVC. “This contract will build upon that work, laying a solid foundation for licensure of this important medical countermeasure in Europe. This work is also an important milestone for DVC, expanding our work beyond U.S. biodefense and into the global arena.”
Scientists working at the U.S. Army Medical Research Institute of Infectious Diseases (USAMRIID) originally identified and developed the vaccine. They identified suitable protein antigens and developed the processes used to assess the performance of the vaccine. DVC further developed and manufactured the vaccine candidate under the U.S. Department of Defense Chemical Biological Medical Systems Joint Vaccine Acquisition Program (CBMS-JVAP) contract. CBMS-JVAP, the UKMOD and the Canadian Department of National Defence are collaborating on the development of this vaccine for the mutual protection of allied military personnel.
The safety and efficacy of this product in humans has not been established. The product is currently under clinical investigation and has not been licensed by the FDA or other regulatory bodies.
*The full name of the USA PATRIOT Act is “Uniting and Strengthening America by Providing Appropriate Tools Required to Intercept and Obstruct Terrorism.”
DynPort Vaccine Company LLC (DVC) manages product development programs and provides consulting, technical and program management services to U.S. government agencies and companies in the biotechnology and pharmaceutical industries. DVC is part of CSC’s North American Public Sector’s Civil and Health Services Group. CSC integrates extensive government health services expertise and commercial best practices to meet federal, state and local healthcare requirements. Services range from optimizing claims processing, to operating disease surveillance systems, to biopharmaceutical product development and management. CSC is improving the quality of health care with better information for better decisions. For more information, visit www.dxc.technology/dvc.
CSC is a global leader in providing technology-enabled solutions and services through three primary lines of business. These include Business Solutions & Services, the Managed Services Sector and the North American Public Sector. CSC’s advanced capabilities include system design and integration, information technology and business process outsourcing, applications software development, Web and application hosting, mission support and management consulting. The company has been recognized as a leader in the industry, including being named by FORTUNE Magazine as one of the World’s Most Admired Companies for Information Technology Services (2010). Headquartered in Falls Church, Va., CSC has approximately 95,000 employees and reported revenue of $16.2 billion for the 12 months ended July 2, 2010. For more information, visit the company’s website at www.dxc.technology.